Ligand Pharmaceuticals (LGND) Operating Leases (2019 - 2026)
Ligand Pharmaceuticals (LGND) posted Operating Leases of $4.0 million for Q1 2026, down 5.02% sequentially from $4.2 million in Q4 2025, and up 399.12% YoY from $800000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Operating Leases (2019 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $4.0 million in Q1 2026.
- Quarterly Operating Leases rose 399.12% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 399.12% YoY) and the FY2025 annual result came in at $4.2 million, down 41.24% from the prior year.
- Operating Leases eased to $4.0 million in Q1 2026 per LGND's latest filing, from $4.2 million in the prior quarter.
- Over five years, Operating Leases peaked at $37.3 million in Q3 2022 and troughed at $800000.0 in Q1 2025.
- A 5-year average of $10.2 million and a median of $6.3 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases jumped 520.18% in 2022, then plunged 84.59% in 2025.
- Over 5 years, Operating Leases stood at $11.1 million in 2022, then sank by 47.95% to $5.8 million in 2023, then climbed by 24.31% to $7.2 million in 2024, then sank by 41.24% to $4.2 million in 2025, then fell by 5.02% to $4.0 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $4.0 million, $4.2 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.78 Mn |
| Mar 31, 2026 | 3.99 Mn |
| Dec 31, 2025 | 4.20 Mn |
| Sep 30, 2025 | 4.42 Mn |
| Jun 30, 2025 | 4.63 Mn |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 7.15 Mn |
| Sep 30, 2024 | 6.27 Mn |
| Jun 30, 2024 | 6.42 Mn |
| Mar 31, 2024 | 5.19 Mn |
| Dec 31, 2023 | 5.76 Mn |
| Sep 30, 2023 | 5.83 Mn |
| Jun 30, 2023 | 10.99 Mn |
| Mar 31, 2023 | 11.18 Mn |
| Dec 31, 2022 | 11.06 Mn |
| Sep 30, 2022 | 37.30 Mn |
| Jun 30, 2022 | 29.59 Mn |
| Mar 31, 2022 | 18.70 Mn |
| Dec 31, 2021 | 2.26 Mn |
| Sep 30, 2021 | 13.65 Mn |